Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Neoplasms 5Breast Neoplasms 2Prostatic Neoplasms, Castration-Resistant 1Prostatic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

enzalutamide 20Abiraterone Acetate 11Prednisone 7Docetaxel 7radium Ra 223 dichloride 6darolutamide 5abiraterone 5apalutamide 3olaparib 2niraparib 2cabazitaxel 2atezolizumab 2Pluvicto 2Nivolumab 2zimberelimab 1xentuzumab 1tasquinimod 1sacituzumab govitecan 1sabizabulin 1quemliclustat 1pembrolizumab 1ipatasertib 1ibrutinib 1gedatolisib 1gallium 68 PSMA-11 1fludrocortisone acetate 1TVB-2640 1Standard of Care 1Rosuvastatin Calcium 1Radium-223 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Prostatic Neoplasms, Castration-Resistant × xentuzumab × Clear all
NCT02204072 2025-07-15

BI836845 Plus Enzalutamide in Castrate Resistant Prostate Cancer (CRPC)

Boehringer Ingelheim

Phase 1 Completed
120 enrolled 28 charts
Genitourinary

Prostatic Neoplasms, Castration-Resistant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡